Home » Current Issue » Association of serum levels of C-reactive protein with CRP-717 T/C polymorphism and viremia in HCV and HBV carriers

Association of serum levels of C-reactive protein with CRP-717 T/C polymorphism and viremia in HCV and HBV carriers

Tuane Carolina Ferreira Moura, Ednelza da Silva Graça Amoras, Maria Alice Freitas Queiroz, Simone Regina Souza da Silva Conde, Alan Barroso Araújo Grisólia, Ricardo Ishak, Antonio Carlos Rosário Vallinoto

1Laboratório de Virologia, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brasil. 2Serviço de Hepatologia, Hospital Santa Casa de Misericórdia do Pará, Belém, PA, Brasil. 3Programa de Pós-Graduação em Biologia de Agentes Infecciosos e Parasitários, Instituto de Ciências Bioloógicas, Universidade Federal do Pará, Belém, PA, Brasil. 4Hospital Universitário João de Barros Barreto, Universidade Federal do Pará, Belém, PA, Brasil. 5Faculdade de Medicina, Instituto de Ciências da Saúde, Universidade Federal do Pará, Belém, PA, Brasil.

DOI: 10.1590/0037-8682-0455-2018



The present study investigated the association of the rs2794521 polymorphism in the CRP gene in individuals with chronic hepatitis B and C, correlating it with markers of hepatic inflammation, fibrosis scores, viral load, and plasma protein levels.


The study analyzed 185 blood samples obtained from patients with hepatitis B (n=74) and hepatitis C (n=111) and 300 samples from healthy donors. Genotyping was performed by real-time polymerase chain reaction, and protein levels were quantified using the automated immunoturbidimetric method.


The TT genotype was the most frequent in all studied groups and was associated with higher plasma levels of the protein but not with the progression of liver disease. Low levels of C-reactive protein were associated with increased viremia and scores indicative of severe fibrosis and cirrhosis.


The present results demonstrated a close relationship between the ability of the virus to replicate and cause liver damage and low serum concentrations of C-reactive protein. Future research may determine if these results can be interpreted as a possible form of escape for the virus by decreasing its action as an opsonin and decreasing phagocytosis, which are functions of C-reactive protein in the immune response.

Keywords: C-reactive protein; SNP; HBV; HCV; Viremia


C-reactive protein (CRP) is synthesized by hepatocytes during acute inflammatory and infectious processes1, as part of the innate immune response of the host, assisting in the elimination of cell debris from necrosis and apoptosis as well as facilitating phagocytosis through its action as an opsonin24. In addition, CRP can lead to activation of the classical pathway of the complement system through binding to the C1q protein23.

Serum levels of CRP may increase over a short time period, especially in the presence of an acute stimulus, such as an infection. In the first few hours, this increase may reach 1,000 times the normal value5. However, mutations in the CRP gene may alter protein function in inflammatory and infectious processes69. Several single nucleotide polymorphisms (SNPs) in the CRP gene were described, and the rs2794521 polymorphism, which is located at position -717 of the promoter region, promotes a T-to-C change and can influence plasma protein levels, once allele T has been correlated with high level of CRP10.

Although the CRP-717 T/C polymorphism is related to the development of acute and chronic inflammatory processes6,7,11, few studies have evaluated this genetic polymorphism in infectious processes3,9,12. In Hepatitis B virus (HBV) infection, CRP-717 T/C polymorphism evaluation has been restricted to the Asian population8,9. In contrast, the effect of this polymorphism on Hepacivirus C (HCV) infection was not evaluated.

Viral hepatitis is a serious public health problem in several regions of the world. Among the viruses that cause hepatitis, HBV and HCV13 are the main viruses responsible for the development of chronic liver diseases14. The World Health Organization estimates that approximately 325 million people live with chronic HBV or HCV infections worldwide15.

In HBV, most chronic carriers develop a partial immune response, which is unable to eliminate the virus, resulting in an active infection with persistent inflammatory activity16. In HCV infection, approximately 50-80% of individuals are unable to eliminate the virus and develop chronic infection17, which may progress to liver failure, the main indication for liver transplantation18.

Considering the important role of CRP in inflammatory processes, which may determine the course of certain diseases, the present study investigated the association of the CRP-717 T/C polymorphism in individuals with chronic HBV and HCV in the State of Pará (Brazil), correlating it with markers of inflammation, fibrosis, viral load and plasma protein levels.


Study population

A cross-sectional study was performed with 185 consecutive cases of chronic HBV (n=74) and HCV (n=111) patients treated at the hepatology outpatient clinic of Holy House of Mercy of Pará Foundation (Fundação Santa Casa de Misericórdia do Pará) and João de Barros Barreto University Hospital of the Federal University of Pará. The study was conducted from May 2013 to June 2016. Inclusion criteria were as follows: individuals aged 18 years and older; individuals of both sexes; individuals with HBsAg for more than 6 months; and HCV-RNA-positive individuals. Individuals who did not meet the requirements set forth above, patients coinfected with hepatitis virus D (HDV) and/or HIV-1 as well as patients who used or were using antiviral therapy against HBV or HCV were excluded from the study.

All selected patients were clinically evaluated and underwent a complementary screening consisting of hematological, biochemical, serological, virological (viral load), ultrasound, and endoscopic tests as well as liver biopsies (METAVIR scoring). Fibrosis score were defined as: 0 to 2, mild and moderate; and 3 to 4, severe and cirrhosis. The degrees of inflammation were: 0 to 1, mild inflammation; and 2 to 3, severe inflammation. These data were transcribed from the medical records to a form designed specifically for the study.

The healthy control group consisted of 300 blood donors from the Fundação de Hemoterapia e Hematologia do Pará (Center of Hematology and Hemotherapy of Pará) who were negative for serological markers of HBV, HCV, and HDV as well as HIV-1. This group was used to compare the genotype and allele frequencies of the CRP –717 T/C polymorphism and plasma protein levels.

The project was submitted to and approved by the Research Ethics Committee of the João de Barros Barreto University Hospital – Universidade Federal do Pará (protocol number 962.537) and the Santa Casa de Misericórdia do Pará (protocol number 772.782) in compliance with the guidelines and regulatory requirements for human research. All participants who agreed to participate signed an informed consent form.

Biological samples

Blood samples (5 mL) were collected using a vacuum collection tube containing ethylenediaminetetraacetic acid as an anticoagulant. The samples were then separated into cells and plasma by centrifugation at 5,000 rpm, and stored at -20 °C until time of use.

DNA extraction

Total DNA extraction from peripheral blood cells was performed according to a previously described protocol19. The procedure included cell lysis, protein precipitation, DNA precipitation and DNA hydration.

CRP -717 T/C polymorphism (rs2794521) analysis

The presence of the CRP –717 T/C polymorphism was investigated in 161 samples from patients with chronic hepatitis, HBV (n=69) and HCV (n=92) by real-time polymerase chain reaction using a StepOne PLUS Sequence Detector (Applied Biosystems, Foster City, CA, USA). Reactions were performed using a predesigned assay (C_318207_20; Life Technologies, Carlsbad, California, USA). Each reaction consisted of 10 μL of TaqMan Universal PCR Master Mix [2X], 1 μL of TaqMan Assay [20X], 6 μL of water and 20 ng of DNA in a final reaction volume of 20 μL. For amplification and detection of alleles, the following program was used: 60 °C for 30 seconds; 95 °C for 10 minutes; and 50 cycles of 92 °C for 30 seconds and 60 °C for 1 minute and 30 seconds.

Plasma quantification of CRP

Plasma levels of CRP were measured by immunoturbidimetry using the CRPeasyDiaSys® kit (DiaSys, Waterbury, CT, USA) on an Architect c8000/Abbott® automated system (Abbott Laboratories Park, Chicago, IL, USA) with a reference < 1 mg/dL.

Statistical analysis

The allele and genotype frequencies were obtained by direct counting. Hardy-Weinberg equilibrium was analyzed on all samples using the Chi-square test (χ 2 ). The comparative analyses of the allele and genotype frequencies were performed through the G-Test and Chi-square (χ 2 ) tests. Comparison analyses of enzyme levels (alanine aminotransferase [ALT]; aspartate aminotransferase [AST]; gamma-glutamyltransferase [GGT]) and viral load (HBV and HCV) with CRP levels were performed using the Mann-Whitney Test and the Spearman’s Test. Statistical analyses were performed using BioEstat 5.3 software20 with a significance level of p < 0.05. Graphs were generated with GraphPad Prism 5.0 software.


Clinical, biochemical and histopathological data for HBV and HCV carrier populations are described in Table 1. The HBV carrier group had a normal mean ALT but elevated levels of AST and GGT. In contrast, the group with HCV infection showed altered levels of all three liver enzymes. In both groups, the majority of patients had mild or moderate fibrosis scores (F0-F2) and absent or mild inflammatory activity levels (A0-A1). Scores indicative of severe fibrosis and cirrhosis (F3-F4) as well as severe inflammatory activity (A2-A3) were found in the group with HCV infection.

TABLE 1: Clinical, biochemical and histopathological data in the population with HBV and HCV. 

Variables HBV HCV
(n=74) (n=111)
Liver enzymes
ALT (IU/L) Mean ± SD 51.03 ± 51.3 77.64 ± 59.27
(08-54 IU/L)
AST (UI/L) Mean ± SD 57.54 ± 79.11 65.35 ± 39.27
(16-40 IU/L)
GGT (IU/L) Mean ± SD 56.21 ± 90.21 96.87 ± 90.76
(<50 IU/L)
Fibrosis scores a
F 0 to 2; n (%) 62 (83.8) 67 (63.3)
F 3 to 4; n (%) 12 (16.2) 34 (33.7)
Inflammatory activity b
A 0 to 1; n (%) 65 (87.8) 54 (58.1)
A 2 to 3; n (%) 09 (12.2) 39 (41.9)

ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: gamma-glutamyltransferase. a Fibrosis score (0 to 2, mild and moderate; and 3 to 4, severe and cirrhosis) METAVIR; b Degree of inflammation (0 to 1, mild inflammation; and 2 to 3, severe inflammation). HBV: Hepatitis B virusHCV: Hepacivirus C.

CRP –717 T/C polymorphism screening showed that the T allele and the TT genotype were the most frequent in the studied groups. However, there was no significant statistical difference between the genotype and allele frequencies of HBV and HCV when compared to the control group (Table 2). The genotype frequencies of the polymorphism were consistent with Hardy-Weinberg equilibrium in studied groups (p > 0.05).

The allele and genotype frequencies did not show significant differences when related to mild (A0-A1) and severe (A2-A3) inflammatory activity levels as well as to mild and moderate fibrosis (F0-F2) and severe fibrosis and cirrhosis (F3-F4) scores (Table 2).

TABLE 2: Distribution of the genotype and allele frequencies of the CRP-717 T/C polymorphism in samples from HBV patients, HCV patients, controls and according to the histopathological aspects of the liver. 

Genetic HBV HCV Control p1 p2 Inflammatory activity Fibrosis score
profile n (%) n (%) n (%) 0 to 1 2 to 3 p3 F0 to F2 F3 to F4 p4
n (%) n (%) n (%) n (%)
TT 44 (63.8) 53 (57.6) 189 (63.0) 0.9846# 0.2406* 69 (61.6) 27 (58.7) 0.8614# 70 (59.8) 27 (61.4) 0.9797#
CT 23 (33.3) 33 (35.9) 103 (34.3) 38 (33.9) 16 (34.8) 41 (35.1) 15 (34.1)
CC 02 (02.9) 06 (06.5) 08 (02.7) 05 (04.5) 03 (06.5) 06 (05.1) 02 (04.5)
*T 0.80 0.76 0.80 1.0000* 0.6086* 0.79 0.76 0.7349* 0.77 0.78 1.0000*
*C 0.20 0.24 0.20 0.21 0.24 0.23 0.22

#G-test, *Chi-square test. p1: HBV vs. control; p2: HCV vs. control. METAVIR; degree of inflammation: p3: 0 to 1(mild inflammation) vs. 2 to 3 (severe inflammation). Fibrosis score: p4: 0 to 2 (mild and moderate – Fibrosis) vs. 3 to 4 (severe and cirrhosis – Cirrhosis) HBV: Hepatitis B virusHCV: Hepacivirus C.

With regard to CRP plasma levels, the concentrations of this protein were significantly higher in the group with HBV infection than in the HCV group (p=0.0213), and both groups had lower concentrations of the protein than the control group although such differences were only statistically significant (p = 0.0011) for the HCV group (Figure 1A).

Compared to the control group, the CRP levels were higher in patients with the TT genotype, but this difference was not statistically significant (Figure 1B). When grouping the patients with viral hepatitis (Figure 1C), however, the CRP levels were significantly higher in patients with TT genotype than those with CT (p = 0.0012) and CC (p = 0.0034) genotypes.

The analysis of the progression of chronic liver disease showed that patients with fibrosis without cirrhosis (F0-F2) had higher levels of CRP (p = 0.0330) compared to patients with severe fibrosis and cirrhosis (F3-F4). In contrast, median plasma viral load levels were higher in patients with altered liver parenchyma with METAVIR F3-F4 scores (Figure 2A and 2D).

Protein levels were higher in patients with mild or absent inflammation (A0-A1) than in those with moderate and severe inflammation (A2-A3), but these differences were not statistically significant. However, viral load levels were higher in patients with a higher degree of inflammation (Figure 2B and 2C).

With regard to liver enzymes (Figure 3A, B, and C), plasma CRP levels were significantly higher in patients who had normal levels of ALT, AST, and GGT. Figure 3D shows a significant negative correlation between plasma viral load and serum CRP levels in both groups of patients with HBV and HCV.

FIGURE1: Serum C-reactive protein concentration. (A) Plasma levels of CRP in the groups of patients with chronic hepatitis B, hepatitis C and controls. (B) Plasma levels of CRP according to genotypes. (C) Plasma levels of CRP according to genotypes in the group of patients with chronic hepatitis B and C. Mann-Whitney test. 

FIGURE 2: Serum C-reactive protein concentration according to infection and clinical conditions of the liver of patients (METAVIR). (A) Plasma levels of CRP in patients with fibrosis without cirrhosis (F0-F2) and in patients with severe fibrosis and cirrhosis (F3-F4). (B) CRP levels according to mild (A0-A1) and severe liver inflammation (A2-A3). (C) Levels of plasma viral load in log10 in patients with fibrosis without cirrhosis (F0-F2) and in patients with cirrhosis (F3-F4). Mann-Whitney test. 

FIGURE 3: Plasma levels of C-reactive protein according to liver enzyme concentrations. (A) Elevated and normal ALT. (B)Elevated and normal AST. (C) Elevated and normal GGT. (D) Spearman correlation between plasma C-reactive protein levels and viral load (log10) of HVB (p=0.0177) and HCV (0.0019). *Mann-Whitney test. **Spearman’s Test. 


The present study showed that the wild-type T allele and the TT genotype of the CRP –717 T/C polymorphism had the highest frequencies in all the studied groups. The present study also demonstrated that the serum concentrations of CRP were higher in the presence of the T allele as compared to the C allele, demonstrating that the production levels of the protein are influenced by this genetic variant. These results corroborated findings related to the wild-type T allele with a higher transcriptional activity of the CRP gene, leading to increased serum protein levels, which may influence an increase in the inflammatory response during early infection6. In addition, the relationship between genotypes and the CRP plasma levels was maintained even in the presence of a chronic liver injury caused by HBV and HCV as demonstrated by elevated levels of liver enzymes and changes in liver parenchyma observed in the study population.

CRP is synthesized in the liver by hepatocytes1 in response to the stimulus produced by interleukin-6 (IL-6) during inflammation and infection21. Hepatitis is characterized by destruction of hepatocytes associated with increased release of inflammatory cytokines, which is characterized by increased liver enzymes22. The present findings reflected these aspects of the pathophysiology of hepatitis. Lower CRP plasma levels are observed in patients with chronic viral hepatitis with a high degree of persistent hepatic injury (F3-F4) and increased ALT, AST and GGT liver enzymes, whereas higher levels are observed in patients with mild and moderate fibrosis (F0-F2) and those with normal liver enzymes2326.

Higher levels of CRP were observed in the serum of patients with HCV prior to treatment with alpha-interferon combined with ribavirin, but the levels decreased after treatment27. The present results showed higher plasma concentrations of CRP in the HBV group than in the HCV group. Importantly, 70% of patients with HBV were inactive carriers as characterized by decreased viral replication and, therefore, less liver damage, resulting in maintenance of hepatocyte integrity.

The present results demonstrated a negative correlation between high plasma viral load levels and low CRP levels. Low serum levels of CRP were strongly associated with viremia in HCV patients23 and elevated levels of IL-6, which is a pro-fibrotic cytokine24. However, the stimulatory effect of IL-6 on CRP production in the liver was not observed in patients with active HCV replication, suggesting that virus replication inhibits the effect of IL-6 on CRP. In the present study, reduced levels of CRP in the group of patients with severe fibrosis (F3-F4) were related to greater viral replication because this group presented higher viral load levels.

The present findings corroborated previous studies demonstrating a close relationship between the ability of the virus to replicate and cause liver damage at low CRP concentrations2,3,28. However, the present results contrast those reported from a previous study that associated high serum concentrations of CRP with increased HBV replication in patients with chronic infection as reflected by the severity of liver damage26. This divergence of results may be related to the methodologies used in data evaluations because unlike the present study25, the previous study used the receiver operating characteristic curve method for analyses.

The present results demonstrated an association of the CRP-717 T/C polymorphism with CRP production levels but not with the progression of chronic infection by HBV and HCV. In contrast, the association found between low serum levels of CRP and increased viremia corroborated the hypothesis of a potential mechanism by which viral replication reduces CRP production29. According to this hypothesis, the local immune response of the host becomes altered or refractory to the continued replication of the virus in hepatocytes, resulting in the following complex events that occur during chronic liver disease caused by viral persistence: impairment of cellular components and immune system products in the liver, death of hepatocytes, establishment of repair fibrosis and low blood flow levels30. These factors lead to the decrease of several local immune response mechanisms, such as the decrease of IL-6 production and consequently, the decrease of CRP production during infection21.

In conclusion, this study showed that HBV and HCV infections are associated with CRP plasma level and chronic liver inflammation. Future research may determine if these findings may be interpreted as a potential escape of the virus from the immune response, and further studies involving other components of the host immune response as well as the effects of using antiviral and antifibrotic therapies that can restore liver function and CRP expression are needed.


We thank all patients who agreed to participate in the study.


1. Snodgrass JJ, Leonard WR, Tarskaia LA, Mcdade TW, Sorensen MV, Alekseev VP, et al. Anthropometric correlates of creactive protein among indigenous Siberians. J Physiol Anthropol. 2007;26(2):241-6. [ Links ]

2. Gershov D, Kim S, Brot N, Elkon KB. C-Reactive Protein Binds to Apoptotic Cells, Protects the Cells from assembly of the Terminal Complement Components, and Sustains an Antiinflammatory Innate Immune Response: Implications for Systemic Autoimmunity. J Exp Med. 2000;192(9):1353-3. [ Links ]

3. Volanakis JE. Human C-reactive protein: expression, structure, and function. J Mol Immunol. 2001;38(2):189-7. [ Links ]

4. Mold C, Baca R, Du Clos TW. Serum Amyloid P Component and C-Reactive Protein Opsonize Apoptotic Cells for Phagocytosis through Fcγ Receptors. J Autoimmun. 2002;19(3):147-4. [ Links ]

5. James K. Cellular and Humoral Mediators of Inflammation: Nonspecific Humoral Response to Inflammation. Clinical Laboratory Medicine. 2 ed. Philadelphia, Lippincott Williams & Wilkins, 2002. [ Links ]

6. Wang L, Lu X, Li Y, Li H, Chen S, Gu D. Functional analysis of the C-reactive protein (CRP) gene -717A>G polymorphism associated with coronary heart disease. BMC Med Genet. 2009;10(73):1-7. [ Links ]

7. Kotlęga D, Białecka M, Kurzawski M, Droździk M, Ciećwież S, Gołąb-Janowska M, et al. Risk factors of stroke and -717A>G (rs2794521) CRP gene polymorphism among stroke patients in West Pomerania province of Poland. Neurol Neurochir Pol. 2014;48(1):30-4. [ Links ]

8. Peng Q, Ren S, Lao X, Lu Y, Zhang X, Chen Z, et al. C-reactive protein genetic polymorphisms increase susceptibility to HBV-related hepatocellular carcinoma in a Chinese population. Tumour Biol. 2014;35(10):10169-6. [ Links ]

9. Lao X, Ren S, Lu Y, Yang D, Qin X, Shan L. Genetic polymorphisms of C-reactive protein increase susceptibility to HBV-related hepatocellular carcinoma in a male population Guangxi. Int J Clin Exp Pathol. 2015;8(12):55-6. [ Links ]

10. Flores-Alfaro E, Fernández-Tilapa G, Salazar-Martínez E, Cruz M, Illades-Aguiar B, Parra-Rojas I. Common variants in the CRP gene are associated with serum C-reactive protein levels and body mass index in healthy individuals in Mexico. Genet Mol Res. 2012;11(3):2258-7. [ Links ]

11. Singh P, Singh M, Nagpal HS, Kaur T, Khullar S, Kaur G, et al. A novel haplotype within C-reactive protein gene influences CRP levels and coronary heart disease risk in Northwest Indians. Mol Biol Rep. 2014;41(9):5851-62. [ Links ]

12. Mölkänen T, Rostila A, Ruotsalainen E, Alanne M, Perola M, Järvinen A. Genetic polymorphism of the C-reactive protein (CRP) gene and a deep infection focus determine maximal serum CRP level in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2010;29(9):1131-7. [ Links ]

13. ICTV (International Committee on Taxonomy of Viruses), 2017. Taxonomic Information. Available from: Available from: https://talk.ictvonline.org/taxonomy/ . Acess: 03/06/2018. [ Links ]

14. Boonstra A, Woltman AM, Janssen ALA. Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol. 2008;22(6):1049-61. [ Links ]

15. WHO. World Health Organization. Global Hepatitis Report 2017. Available from:http://apps.who.int/iris/bitstream/handle/10665/255016/9789241565455-eng.Pdf;js essionid=FDC426FCAE1849E06C1E9CD3B61D73CF?sequence=1. Acess: 04/05/2018. [ Links ]

16. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B vírus infection. J Hepatol. 2005;46:160-70. [ Links ]

17. Seeff LB. Natural history of chronic hepatitis C. Hepatol. 2002;36(5):35-46. [ Links ]

18. Shaw-Stiffel T. Reference to Hepatitis C Infection. London: Science Press, 2004. [ Links ]

19. Cigliero SS, Edalucci E, Fattorini P. DNA extractor from blood and forensic samples. Guidelines for Molecular Analysis in Archive Tissues. 2011;45-54. [ Links ]

20. Ayres M, Ayres Júnior M, Ayres DL, Santos AS. BioEstat 5.0: statistical applications in the biological and medical sciences. Belém: Sociedade Civil Mamirauá; Brasília: CNPq; 2007;01- 272. [ Links ]

21. Pepys MB, Baltz ML. Acute phase proteins with special reference to C reactive protein and related proteins (pentaxins) and serum amyloid a protein. Adv Immunol. 1983;34:121-41. [ Links ]

22. Ferreira MS. Diagnosis and treatment of hepatitis B. Rev Soc Bras Med Trop. 2000;33(4):389-00. [ Links ]

23. Salter ML, Lau B, Mehta SH, Go VF, Leng S, and Kirk GD. Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections. J Acquir Immune Defic Syndr. 2013;64(5):488-95. [ Links ]

24. Shah S, Ma Y, Scherzer R, Huhn G, French AL, Plankey M, et al. Association of HIV, hepatitis C virus and liver fibrosis severity with interleukin-6 and C-reactive protein levels. 2015; AIDS,29(11):1325-33. [ Links ]

25. Yilmaz H, Yalcin S, Namuslu M, Celik HT, Sozen M, Inan O, et al. Lymphocyte Neutrophils Ratio (NLR) could be a better predictor of C-reactive protein (CRP) for liver fibrosis in non-alcoholic steatohepatitis (NASH). Ann Clin Lab Sci. 2015;45(3):278-86. [ Links ]

26. Ma LN, Liu XY, Luo X, Hu YC, Liu SW, Tang YY, et al. High sensitivity to serum C-reactive protein are associated with the replication of HBV, liver damage and fibrosis in patients with chronic hepatitis B infection. Hepatogastroenterology. 2015;62(138):368-72. [ Links ]

27. Huang CF, Hsieh MY, Yang JF, Chen WC, Yeh ML, Huang CI, et al. Serumhs-CRP was correlated with treatment response topegy lated interferon andribavirin combination therapy in chronic hepatitis C patients. Hepatol Int. 2010;4(3):621-27. [ Links ]

28. Mold C, Baca R, Du Clos TW. Serum Amyloid P Component and C-Reactive Protein Opsonize Apoptotic Cells for Phagocytosis through Fcγ Receptors. J Autoimmun. 2002;3(19):147-54. [ Links ]

29. Gale MJr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature. 2005;436(7053):939-45. [ Links ]

30. Huang WP, Jiang WQ, Hu B, Ye H, Zeng HZ. Significance of serum procalcitonin levels in the evaluation of severity and prognosis of patients with systemic inflammatory response syndrome. Zhongguo Wei zhong bing Ji jiu Yi xue.2012;24(5):294-7. [ Links ]

Financial Support: The study was funded by the Brazilian National Council for Scientific and Technological Development (CNPq # 480128/2013-8) and the Universidade Federal do Pará (PROPESP/PAPQ/2018).

Received: November 05, 2018; Accepted: January 04, 2019

Corresponding author: Dr. Antonio Carlos Rosário Vallinoto. e-mail:vallinoto@ufpa.brOrcid: 0000-0003-1135-6507

Conflict of interest: The authors declare that there is no conflict of interest.